GSK/Theravance file GSK 573719 plus vilanterol at the EMA for COPD
GlaxoSmithKline and Theravance have announced the submission of a regulatory application to the EMA for the investigational once-daily LAMA/LABA combination medicine, UMEC/VI, for patients with Chronic Obstructive Pulmonary Disease (COPD).
UMEC/VI is a combination of two investigational bronchodilator molecules -- GSK 573719 or umeclidinium bromide (UMEC), a long-acting muscarinic antagonist and vilanterol (VI), a long-acting beta2 agonist ,administered using the ELLIPTA inhaler. The proposed name of the combination is Anoro.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.